Genmab (GMAB) AGM 2020 summary
Event summary combining transcript, slides, and related documents.
AGM 2020 summary
26 Oct, 2026Opening remarks and agenda
At the AGM on March 26, 2020, the Chair reported on the prior year, the CEO presented plans for 2020, and the CFO presented the audited 2019 Annual Report.
Financial performance review
The 2019 Annual Report was approved; DKK 2,166 million in annual profit was transferred to retained earnings.
Board and executive committee updates
Jonathan Peacock was elected for a one-year term; Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Paolo Paoletti and Anders Gersel Pedersen were re-elected for one-year terms.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Genmab
- FY2020 results approved; directors re-elected and governance, remuneration and capital proposals passed.GMAB
AGM 2021 - FY2021 accounts approved, DKK 3,008 million retained, and one new director elected.GMABAGM 2022
- AGM approved the 2022 accounts and adopted board, remuneration and treasury-share proposals.GMABAGM 2023
- 2023 accounts approved; directors re-elected and governance and capital proposals adopted.GMABAGM 2024
- Rina-S significantly improved PFS and OS in Phase 3 platinum-resistant ovarian cancer trial.GMABStudy result
- AbbVie collaboration pairs three bispecific programs with up to four discovery candidates.GMABCollaboration
- Proposed 2026 board pay combines cash fees, RSUs and committee meeting payments.GMABEGM 2026 presentation
- Pivotal phase III oncology readouts in Q4 2026 set up three major launches in 2027.GMABBank of America Global Healthcare Conference
- Rina-S® showed durable activity in gynecologic cancers, advancing toward Phase 3.GMABR&D Update